TrevorFeinsteinMD

PubMed

• 19 citations
  Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer:...
  Renata Ferrarotto, Ian Anderson, Balazs Medgyasszay, Maria Rosario García-Campelo, William Jeffery Edenfield, Trevor M. Feinstein, Jennifer Johnson, Sujith Kalmadi, Ph...> ;Cancer Medicine. 2021 Sep 1
• 17 citations
  Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies
  Athanassios Argiris, T. M. Feinstein, Lin Wang, Tianbing Yang, Shruti Agrawal, Leonard Joseph Appleman, Ronald G. Stoller, Jennifer R. Grandis, Ann Marie Egloff> ;Investigational New Drugs. 2012 Aug 1
• Serum biomarkers as predictors of clinical outcome after cetuximab-based therapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
  Ferris RL, Feinstein T, Grandis J, Johnson R, Branstetter B, Gooding W, Argiris A> ;J. Clin. Oncol.. 2009-05-20
• Blood biomarker modulation with dasatinib (D) and cetuximab (C) in patients (pts) with advanced solid malignancies.
  Egloff A, Feinstein TM, Joyce SC, Kelly LA, Panelli MC, Yang T, Siegfried JM, Grandis JR, Argiris A> ;J. Clin. Oncol.. 2009-05-20
• TS and MTHFR gene polymorphisms in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head or neck (SCCHN) treated with pemetrexed (P) and beva...
  Romkes M, Feinstein TM, Zhong S, Buch S, Gibson MK, Skovira K, Argiris A> ;J. Clin. Oncol.. 2009-05-20
• Phase I and pharmacokinetic (PK) study of dasatinib (D) and cetuximab (C) in patients (pts) with advanced solid malignancies.
  Feinstein TM, Agrawal S, Stoller RG, Egorin MJ, Argiris A> ;J. Clin. Oncol.. 2009-05-20
• Prognostic factors in patients with locally advanced salivary gland cancers treated with surgery and postoperative radiotherapy (RT).
  Lai SY, Feinstein TM, Seethala RR, Heron DE, Ferris RL, Grandis JR, Myers EN, Johnson JT, Argiris AE> ;J. Clin. Oncol.. 2008-05-20
• Pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC): updated results of a phase II trial.
  Feinstein TM, Raez LE, Rajasenan KK, Gibson MK, Savvides P, Karamouzis MV, Garg N, Johnson R, Branstetter BF, Argiris AE> ;J. Clin. Oncol.. 2008-05-20
• 41 citations
  Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer
  Athanassios Argiris, Steve C. Lee, T. M. Feinstein, Sufi M. Thomas, Barton F. Branstetter, Raja R. Seethala, Lin Wang, William E. Gooding, Jennifer R. Grandis, Robert ...> ;Oral Oncology. 2011 Oct 1
• 31 citations
  Prognostic factors in patients with high‐risk locally advanced salivary gland cancers treated with surgery and postoperative radiotherapy
  T. M. Feinstein, Stephen Y. Lai, Diana Lenzner, William E. Gooding, Robert L. Ferris, Jennifer R. Grandis, Eugene N. Myers, Jonas T. Johnson, Dwight E. Heron, Athanass...> ;Head & Neck. 2011 Mar 1
• 17 citations
  Cetuximab-induced aseptic meningitis
  T. M. Feinstein, Michael K. Gibson, Athanassios Argiris> ;Annals of Oncology. 2009 Sep 1
• Join now to see all